Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

Risultato della ricerca: Articlepeer review

1 Citazioni (Scopus)

Abstract

Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.
Lingua originaleEnglish
Numero di pagine9
RivistaCurrent Medicinal Chemistry
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Entra nei temi di ricerca di 'Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide'. Insieme formano una fingerprint unica.

Cita questo